Merus: Riding The Bispecific Wave In Oncology

The oncology drug development landscape is competitive and requires innovation and clinical validation. In this space, companies leveraging novel platform technologies to create differentiated therapies stand out. With its focus on Biclonics and Multiclonics bispecific and multispecific antibodies, Merus (I have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forwar ...